1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Feng Chi Biotech Corp.

Feng Chi Biotech Corp.

TTPEX:6744
14.45
TWD
0.00
(0.00%)
234.08MMarket Cap
Feng Chi Biotech Corp.
TPEX:6744
(Taipei Exchange)

Recent

price

14.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.77
9.72
11.49
11.66
11.62
11.86
12.58
11.73
11.11
11.52
- -
Revenue per Share
1.57
1
1.3
1.16
1.65
1.5
1.6
1.48
1.08
0.94
- -
Basic EPS, GAAP
1.81
0.47
2.88
1.28
2.35
2.07
1.84
0.91
0.68
-0.64
- -
Free Cash Flow per Basic Share
0.2
0.56
0.63
0.88
0.9
1.15
1.25
1.35
1.05
0.95
- -
Dividend per Share
8.72
10
11.5
13.87
14.62
14.97
15.32
15.45
15.58
15.58
14.9
Book Value per Share
8.7
9.99
11.5
13.86
14.61
14.97
15.31
15.45
15.58
15.57
14.9
Tangible Book Value per Share
10
13
13
15
15
15
15
15
15
15
15
Basic Weighted Avg Shares
140
125
148
174
179
183
193
181
171
177
- -
Sales/Revenue/Turnover
11.52
13.57
12.7
11.47
15.98
14.48
13.99
13.38
9.42
7.81
- -
Operating Margin (%)
3
6
7
8
10
9
6
7
9
12
- -
Depreciation Expense
16
13
17
17
25
23
25
23
17
14
- -
Net Income, GAAP
17.85
21.37
18.66
19.97
14.86
17.55
19.08
16.51
18.39
14.52
- -
Effective Tax Rate (%)
11.38
10.3
11.35
9.96
14.19
12.67
12.72
12.62
9.7
8.16
- -
Profit Margin (%)
114
125
155
191
205
210
214
200
193
187
175
Working Capital
- -
- -
- -
5
3
- -
11
8
5
3
1
LT Debt
134
154
177
214
225
231
236
238
240
240
230
Total Equity
- -
9.08
9.11
7.96
10.64
9.31
9
8.03
5.28
4.79
- -
Return on Invested Capital (%)
- -
8.91
10.15
8.72
11.3
10.02
10.22
9.26
6.76
5.93
- -
Return on Capital (%)
- -
8.91
10.15
8.89
11.58
10.16
10.56
9.62
6.94
6.03
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
315
274
234

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
247
233
225
Cash, Cash Equivalents & STI
192
179
172
Accounts Receivable, Net
16
10
21
Inventories
31
35
31
Total Current Liabilities
68
45
50
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.29%
0.01%
Free Cash Flow
- -
-58.76%
-194.59%
Net Income, GAAP
- -
-9.97%
-12.78%
Sales/Revenue/Turnover
- -
-0.05%
3.66%
Total Cash Common Dividend
- -
2.55%
-9.52%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
171
2025
- -
- -
177
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.08
2025
- -
- -
0.94
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.05
2025
- -
- -
0.95
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Feng Chi Biotech Corp. (6744.TWO) engages primarily in genetic testing and diagnostic services across reproductive health, precision medicine, and microbiological analysis. The company offers preimplantation genetic testing including preimplantation genetic screening (PGS) and diagnosis (PGD); prenatal testing services; precision medicine solutions; newborn screening for genetic and inherited diseases; food and pharmaceutical microbiological testing; medical translational research; and distribution of genetic testing technologies such as Agena MassARRAY MALDI-TOF systems for high-throughput nucleic acid detection and ArcherDX NGS library kits utilizing Anchored Multiplex PCR for oncology applications including cancer precision tests. Founded in 1992 and headquartered in Taipei City, Taiwan, Feng Chi Biotech operates mainly in the Taiwan market, serving healthcare providers, research institutions, and pharmaceutical clients with exclusive distribution rights for key life science products like Agena MassARRAY reagents and instruments, complemented by after-sales training and protocol development support. In recent developments, the company maintains its focus on certified service provision as an Agena partner for customizable genetic data analysis reports, with no major acquisitions, funding rounds, or strategic partnerships announced in 2024 or 2025, while sustaining operations in biotechnology amid a market capitalization of approximately NT$290 million.